Isis Pharmaceuticals, Inc. (KVPHQ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 18, 2014
Pages: 82
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IC77885466AEN
Leaflet:

Download PDF Leaflet

Isis Pharmaceuticals, Inc. (KVPHQ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Isis Pharmaceuticals, Inc. (Isis) is a bio-pharmaceutical company. The company specializes in anti-sense technology. It carries out the discovery and development of new class antisense drugs that address significant unmet medical needs. Antisense technology is a direct route from genomics to drugs. KYNAMRO (mipomersen sodium) injection is the lead product candidate of the company which has been developed in collaboration with Genzyme. It is used for the reduction of low-density lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH. The product pipeline of the company focuses on various therapeutic areas, namely, cardiovascular, cancer, metabolic, neurodegenerative, inflammatory and other diseases. The products in the pipeline include ISIS-CRP, ISIS-FXI and ISIS-APO(a). Isis is headquartered in Carlsbad, California, the US.

Isis Pharmaceuticals, Inc. (KVPHQ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Medical Devices Deals, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Regulus Therapeutics Secures US$20 Million In Venture Financing
Regulus Therapeutics Raises US$10 Million In Venture Financing
Altair Therapeutics Secures US$17 Million In Venture Financing Round
Regulus Therapeutics Secures US$20 Million In Series A Preferred Equity Financing
Partnerships
AstraZeneca Expands Co-Development Agreement with Isis Pharma
Regulus Therapeutics Expands Agreement With Sanofi
SQI Diagnostics Enters Into Agreement With Isis Pharma To Develop Multiplexed Assay
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders
Regulus Therapeutics Enters Into Co-Development Agreement With AstraZeneca For MicroRNA Therapeutics
Regulus Therapeutics Expands Agreement With Sanofi-Aventis
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma
Regulus Therapeutics Enters Into Collaboration With University of California
Isis Pharma Enters Into Collaboration With Xenon Pharma
Sanofi-aventis Enters Into Strategic Alliance With Regulus Therapeutics
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma
Regulus Therapeutics Enters Into An Agreement With GlaxoSmithKline
Cenix BioScience Enters Into Co-Development Agreement With Regulus Therapeutics
OncoGenex Technologies Amends Co-Development Agreement With Isis Pharma
GlaxoSmithKline Enters Into An Agreement With Regulus Therapeutics
Licensing Agreements
Regulus Therapeutics Enters Into Option For Licensing Agreement With Sanofi
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701
Isis Pharma Enters Into Licensing Agreement With AstraZeneca
GlaxoSmithKline Amends Licensing Agreement With Isis Pharma For ISIS-TTRRx
Regulus Therapeutics Enters Into Licensing Agreement With New York University
Regulus Therapeutics Enters Into Licensing Agreement With University of Wuerzburg And Bayerische
Atlantic Healthcare Enters Into Licensing Agreement With Isis Pharma
GlaxoSmithKline Enters Into Licensing Agreement With Isis Pharma
Regulus Therapeutics And Isis Pharma Enter Into Licensing Agreement With California Institute of Technology
Verva Pharma Enters Into Licensing Agreement With Isis Pharma
Alnylam Pharma Enters Into Licensing Agreement With Isis Pharma
Isis Pharma Enters Into Licensing Agreement With Genzyme
Regulus Therapeutics Signs Licensing Agreement With Stanford University
Equity Offering
Regulus Therapeutics Raises USD82 Million in Public Offering of Shares
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million
Regulus Therapeutics Completes Public Offering Of Shares For US$49.2 Million
Isis Pharma Completes Public Offering Of Shares For US$182.7 Million
Regulus Announces Partial Exercise Of Underwriter’s Option For IPO For US$51 Million
Regulus Therapeutics Completes Private Placement Of Shares For US$25 Million
iCo Therapeutics Completes Private Placement Of US$0.91 Million Upon Exercise Of Warrants
Debt Offering
Isis Pharma Prices Private Placement of 1% Notes Due 2021 for USD425 Million
Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For US$201 Million
Regulus Therapeutics Completes Private Placement Of Notes For US$5 Million With GlaxoSmithKline
Asset Transactions
novosom Acquires CD40 License From Isis Pharma
Acquisition
Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma
Isis Pharmaceuticals, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2013
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Deals By Therapy Area, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Medical Devices Deals, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Regulus Therapeutics Secures US$20 Million In Venture Financing
Regulus Therapeutics Raises US$10 Million In Venture Financing
Altair Therapeutics Secures US$17 Million In Venture Financing Round
Regulus Therapeutics Secures US$20 Million In Series A Preferred Equity Financing
AstraZeneca Expands Co-Development Agreement with Isis Pharma
Regulus Therapeutics Expands Agreement With Sanofi
SQI Diagnostics Enters Into Agreement With Isis Pharma To Develop Multiplexed Assay
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders
Regulus Therapeutics Enters Into Co-Development Agreement With AstraZeneca For MicroRNA Therapeutics
Regulus Therapeutics Expands Agreement With Sanofi-Aventis
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma
Regulus Therapeutics Enters Into Collaboration With University of California
Isis Pharma Enters Into Collaboration With Xenon Pharma
Sanofi-aventis Enters Into Strategic Alliance With Regulus Therapeutics
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma
Regulus Therapeutics Enters Into An Agreement With GlaxoSmithKline
Cenix BioScience Enters Into Co-Development Agreement With Regulus Therapeutics
OncoGenex Technologies Amends Co-Development Agreement With Isis Pharma
GlaxoSmithKline Enters Into An Agreement With Regulus Therapeutics
Regulus Therapeutics Enters Into Option For Licensing Agreement With Sanofi
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701
Isis Pharma Enters Into Licensing Agreement With AstraZeneca
GlaxoSmithKline Amends Licensing Agreement With Isis Pharma For ISIS-TTRRx
Regulus Therapeutics Enters Into Licensing Agreement With New York University
Regulus Therapeutics Enters Into Licensing Agreement With University of Wuerzburg And Bayerische
Atlantic Healthcare Enters Into Licensing Agreement With Isis Pharma
GlaxoSmithKline Enters Into Licensing Agreement With Isis Pharma
Regulus Therapeutics And Isis Pharma Enter Into Licensing Agreement With California Institute of Technology
Verva Pharma Enters Into Licensing Agreement With Isis Pharma
Alnylam Pharma Enters Into Licensing Agreement With Isis Pharma
Isis Pharma Enters Into Licensing Agreement With Genzyme
Regulus Therapeutics Signs Licensing Agreement With Stanford University
Regulus Therapeutics Raises USD82 Million in Public Offering of Shares
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million
Regulus Therapeutics Completes Public Offering Of Shares For US$49.2 Million
Isis Pharma Completes Public Offering Of Shares For US$182.7 Million
Regulus Announces Partial Exercise Of Underwriter’s Option For IPO For US$51 Million
Regulus Therapeutics Completes Private Placement Of Shares For US$25 Million
iCo Therapeutics Completes Private Placement Of US$0.91 Million Upon Exercise Of Warrants
Isis Pharma Prices Private Placement of 1% Notes Due 2021 for USD425 Million
Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For US$201 Million
Regulus Therapeutics Completes Private Placement Of Notes For US$5 Million With GlaxoSmithKline
novosom Acquires CD40 License From Isis Pharma
Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma
Isis Pharmaceuticals, Inc., Key Competitors
Isis Pharmaceuticals, Inc., Key Employees
Isis Pharmaceuticals, Inc., Subsidiaries

LIST OF FIGURES

Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Isis Pharmaceuticals, Inc., Medical Devices Deals, 2008 to YTD 2014
Skip to top


Ask Your Question

Isis Pharmaceuticals, Inc. (KVPHQ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: